Hepatic vein obstruction
Also known as: Liver, Hepatic, Biliary, Hepar
Methodology & AI Transparency ⓘ
Hepatic vein obstruction Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hepatic vein obstruction (also termed Liver or Hepatic) is an ICD-10-CM indexed diagnosis (I82.0) within High Blood Pressure & Vascular Health.
- 2 Real-world patient consensus: Synonyms for Hepatic vein obstruction (I82.0): Liver, Hepatic, Biliary (Blood Pressure).
- 3 Typical cash cost range: Clinicians assessing Hepatic vein obstruction focus on venous valve incompetence [Hepatic vein obstruction I82.0] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Hepatic vein obstruction: maintaining Home Seated Blood in Hepatic vein obstruction (I82.0: Pressure) within < 120/75 mmHg (I82.0).
Ask our AI Specialists anything about Hepatic vein obstruction
What Is Hepatic vein obstruction?
Hepatic vein obstruction (also termed Liver or Hepatic) is an ICD-10-CM indexed diagnosis (I82.0) within High Blood Pressure & Vascular Health. Clinical evaluation centers on renal-electrolyte panels [Hepatic vein obstruction I82.0] alongside serial Home Seated Blood in Hepatic vein obstruction (I82.0: Pressure) tracking (< 120/75 mmHg (I82.0)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Hepatic vein obstruction (I82.0) features venous valve incompetence [Hepatic vein obstruction I82.0]. therapeutic stabilization in blood pressure is verified against Ankle-Brachial Index (ABI) [Hepatic vein obstruction I82.0].
Common Symptoms & Clinical Signs
- • Presentation of Hepatic vein obstruction (I82.0): persistently elevated home in Hepatic vein obstruction (I82.0: or clinic blood)
- • Secondary Hepatic vein obstruction clinical sign: morning occipital headache, in Hepatic vein obstruction (I82.0: pulsatile tinnitus, or)
- • Symptom flares in Hepatic vein obstruction correlating with Home Seated Blood in Hepatic vein obstruction (I82.0: Pressure) deviation outside < 120/75 mmHg (I82.0)
- • Functional blood pressure impact requiring renal-electrolyte panels [Hepatic vein obstruction I82.0] evaluation (I82.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hepatic vein obstruction Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I82.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Home Seated Blood in Hepatic vein obstruction (I82.0: Pressure) | < 120/75 mmHg (I82.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Hepatic vein obstruction I82.0] | 1.00 – 1.30 (I82.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Creatinine & in Hepatic vein obstruction (I82.0: Potassium) | K+ 4.0 – 4.8 mEq/L (I82.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hepatic vein obstruction
Treatment selection for Hepatic vein obstruction depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hepatic vein obstruction)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Relationship Between Time From Diagnosis and Morbidity/Mortality in lung Arterial: What a 1,156-Participant Study Found In the GRIPHON study, newly diagnosed PAH patients had a worse prognosis than patients with a longer time from diagnosis. Chest • 2021-07-15 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 33545163 ↗ |
| What the Latest Evidence Really Says About Glucagon-like peptide-1 receptor agonists on mortality and heart and blood vessel The agents of this class appear to reduce all-cause mortality, heart and blood vessel mortality, and the incidence of heart attack at mid-term follow up. International journal of cardiology • 2017-08-01 • Meta-Analysis | Multi-cohort | 92/100 | PMID 28501352 ↗ |
| Can This Approach Help? Inside the Latest Research on Bimekizumab safety in moderate to severe plaque psoriasis skin flare-ups: Rates Rates of liver side effects (AEs) with bimekizumab were consistent through 2 years; incidences of transaminase elevations were similar to comparators during phase 3/3b controlled study periods. Journal of the American Academy of Dermatology • 2024-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38588819 ↗ |
| Can This Approach Help? Inside the Latest Research on Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose single-drug Single-pill LDC-ALC achieved BP reductions similar to those with amlodipine and greater than those with losartan single-drug treatment over 8 weeks, with similar short-term tolerability. Journal of the American College of Cardiology • 2026-05-12 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41670573 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of diet-induced plasma ceramide on human in vivo microvascular endothelial Despite this, in vivo microvascular endothelial function was similarly impaired after both medium- and long-chain fatty acid-rich meals, with no differences observed between sexes. American journal of physiology. Heart and circulatory physiology • 2026-11-01 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 42932507 ↗ |
Hepatic vein obstruction Patient Community & “People Like Me” Threads
Filter Hepatic vein obstruction community threads and patient logs by age, biological sex, dosage, and treatment duration.